News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Studies Highlight The Potential Of Liraglutide, Novo Nordisk’s Investigational GLP-1 Analogue
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Long-Acting Analogue Offers Improved Blood Glucose Control, Weight Control and Low Risk of Hypoglycaemia, in a Once-Daily Treatment
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Novo Nordisk
MORE ON THIS TOPIC
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
May 12, 2025
·
2 min read
·
Tristan Manalac
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
·
7 min read
·
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
